Payment overview · 2025
General Payments
$1,441.08
80 reported records · 8 companies
Healthcare provider profile · identity verified
Jose M. Marcial Suarez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · CAYEY, PR · NPI 1124334875
Verified facts
What the public records show
CMS Open Payments records show Jose M. Marcial Suarez, M.D. received $1,441.08 in general payments during 2025 across 80 reported records.
Abbott Laboratories accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 522 claims for Eliquis by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 522 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $460.93 | 32.0% | 38 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $440.21 | 30.6% | 26 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$263.66 | 18.3% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $112.52 | 7.8% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $80.25 | 5.6% | 3 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $44.79 | 3.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.95 | 1.6% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $15.77 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,441.08 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $273.95 | 13 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $230.22 | 4 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $132.73 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $112.52 | 4 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $111.12 | 17 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $109.53 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $80.25 | 3 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $64.05 | 14 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PBG PUERTO RICO LLC | $44.79 | 2 | 2025 |
Source payment records
|
|||||
| INGEVITY+ Normalized: ingevity |
Device | Boston Scientific Corporation | $33.02 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $32.48 | 1 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $25.88 | 2 | 2025 |
Source payment records
|
|||||
| ACUITY Steerable Normalized: acuity steerable |
Device | Boston Scientific Corporation | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $21.98 | 2 | 2025 |
Source payment records
|
|||||
| PORTICO Normalized: portico |
Device | Abbott Laboratories | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PBG PUERTO RICO LLC | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| General - Angioplasty Normalized: general angioplasty |
Device | Boston Scientific Corporation | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $16.44 | 4 | 2025 |
Source payment records
|
|||||
| ARMADA Normalized: armada |
Device | Abbott Laboratories | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| MERLIN@HOME Normalized: merlin home |
Device | Abbott Laboratories | $6.22 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $4.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 522 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
522 | 128 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
522 | 128 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 613 | 139 |
| Metoprolol Succinate | Metoprolol Succinate | 556 | 131 |
| Eliquis | Apixaban | 522 | 128 |
| Losartan Potassium | Losartan Potassium | 375 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 53 |
| Lisinopril | Lisinopril | 222 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 201 | 48 |
| Nifedipine Er | Nifedipine | 195 | 50 |
| Furosemide | Furosemide | 192 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 49 |
| Carvedilol | Carvedilol | 171 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 33 |
| Flecainide Acetate | Flecainide Acetate | 145 | 32 |
| Entresto | Sacubitril/Valsartan | 136 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 36 |
| Irbesartan | Irbesartan | 98 | 21 |
| Jardiance | Empagliflozin | 96 | 14 |
| Cephalexin | Cephalexin | 83 | 82 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 18 |
| Xarelto | Rivaroxaban | 56 | 15 |
| Spironolactone | Spironolactone | 52 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 11 |
| Famotidine | Famotidine | 40 | 11 |
| Simvastatin | Simvastatin | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 37 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Omeprazole | Omeprazole | 34 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Metformin Hcl | Metformin Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 18 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 16 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 15 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,441.08 · 80 records | Abbott Laboratories | ACUITY Steerable, ARMADA, ARTIX MT, ASSURITY, AVEIR, CAMZYOS, COREVALVE EVOLUT R, ELIQUIS, ENSITE PRECISION, FARAPULSE, GALLANT, General - Angioplasty, General - Therapies, INGEVITY+, JARDIANCE, JOT DX, LifeVest, MERLIN@HOME, PAXLOVID, PORTICO, PULSESELECT, SUPERA, SYMPLICITY G3, WATCHMAN FLX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error